Compare Sana Biotechnology Inc (SANA) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Select Medical Holdings Corporation — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Select Medical Holdings Corporation is far larger — about 2.3× Sana Biotechnology Inc's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SEM | |
|---|---|---|
Market Cap | $873.84M | $2.05B |
Sector | Health | Health |
52-Week High | $5.92 | $16.66 |
52-Week Low | $2.68 | $11.77 |
Enterprise Value | $848.03M | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Select Medical (SEM) trades at $16.51, unchanged on the day, amid a completed acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock shows a bullish technical signal with support and resistance clustered around $17. Financially, the company reported 2025 revenue of $5.45B and net income of $146.22M, with a P/E of 15.43 and P/S of 0.36 indicating moderate valuation. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into the board's fiduciary duties posing a key risk. Analyst sentiment is mixed with 35.71% buy ratings but 57.15% hold, reflecting uncertainty post-buyout. Investors should note the stock's limited movement potential given the acquisition price, with fundamental performance and legal outcomes driving any residual value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
